Equities researchers at FBR & Co began coverage on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a research note issued on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $206.00 price target on the specialty pharmaceutical company’s stock. FBR & Co’s target price suggests a potential upside of 43.01% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $192.00 target price (up previously from $180.00) on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 9th. Zacks Investment Research raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $174.00 target price for the company in a report on Tuesday, August 8th. Leerink Swann upped their target price on shares of Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, July 4th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $176.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, July 4th. Finally, Vetr raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $165.11 target price for the company in a report on Tuesday, June 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $180.88.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down 0.66% during trading on Thursday, hitting $144.05. The stock had a trading volume of 299,602 shares. The company has a market capitalization of $8.65 billion, a P/E ratio of 22.19 and a beta of 1.05. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The stock’s 50-day moving average price is $147.72 and its 200-day moving average price is $151.35.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.85 by ($0.13). The firm had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The company’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the prior year, the company posted $2.67 EPS. Analysts expect that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Jazz Pharmaceuticals PLC (JAZZ) Now Covered by Analysts at FBR & Co” was published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/22/jazz-pharmaceuticals-plc-jazz-now-covered-by-analysts-at-fbr-co.html.

In related news, Director Paul L. Berns sold 662 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $142.37, for a total transaction of $94,248.94. Following the transaction, the director now directly owns 6,599 shares in the company, valued at approximately $939,499.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paul Treacy sold 1,304 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $143.32, for a total transaction of $186,889.28. The disclosure for this sale can be found here. Insiders have sold a total of 4,517 shares of company stock worth $665,623 over the last quarter. 4.30% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of JAZZ. Toronto Dominion Bank grew its holdings in Jazz Pharmaceuticals PLC by 12.4% during the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after purchasing an additional 81 shares during the last quarter. US Bancorp DE grew its stake in Jazz Pharmaceuticals PLC by 94.4% in the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after acquiring an additional 368 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in Jazz Pharmaceuticals PLC by 43.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after acquiring an additional 295 shares in the last quarter. Gargoyle Investment Advisor L.L.C. bought a new position in Jazz Pharmaceuticals PLC in the 2nd quarter worth about $206,000. Finally, Janney Montgomery Scott LLC bought a new position in Jazz Pharmaceuticals PLC in the 2nd quarter worth about $211,000. Institutional investors own 87.82% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.